Sage Therapeutics (SAGE) Posts Q2 Loss of $4.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Leerink Swann Starts Sage Therapeutics (SAGE) at Outperform
August 12, 2014 7:46 AM EDTLeerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Sage Therapeutics (SAGE) at Buy
August 12, 2014 7:45 AM EDT(Updated - August 12, 2014 11:16 AM EDT)
Canaccord Genuity initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $40.00.
Analyst John Newman said, "We are initiating coverage on SAGE Therapeutics... More
JPMorgan Starts Sage Therapeutics (SAGE) at Overweight
August 12, 2014 7:45 AM EDTJPMorgan initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Overweight rating and a price target of $42.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $33.40 yesterday.
... MoreGoldman Sachs Starts Sage Therapeutics (SAGE) at Neutral
August 12, 2014 7:44 AM EDTGoldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.
Analyst Navdeep Singh said, "Sage is a small-cap biotech focused on developing drugs for central nervous... More
